Ambu A/s Class B · OMXCOP:AMBU_B

Ambu A/s Class B — Q1 2007/08 Earnings Presentation

19 slides from Ambu A/s Class B's earnings presentation, Jan 29, 2008

  1. Slide 1: Q1 2007/08 presentation, 29 January 2008

    Q1 2007/08 presentation, 29 January 2008 By K. E. Birk, CEO, Anders Arvai, CFO, and Henrik Wendler, COO

  2. Slide 2: Agenda

    Agenda  Developments in Q1  Outlook for 2007/08  Focus areas in the coming period October 28, 2026 2

  3. Slide 3: Highlights – Q1 2007/08

    Highlights – Q1 2007/08  Revenue of DKK 187m – up 14% (19% in local currencies)  Sales to the USA up 44%  EBIT of DKK 16m against DKK 9m in Q1 2006/07  EBIT margin of 8.8% against 5.7% in Q1 2006/07  Profit before tax of DKK 13m against DKK 6m in Q1 2006/07  Free cash flow of DKK 16m against D

  4. Slide 4: Revenue

    Revenue  Revenue of DKK 187m against DKK 164m last year  The revenue was affected by special conditions in the USA in Q4 2006/07 – trading with most customers resumed  Negative effect of exchange rates of approx. DKK 8m in Q1  New products contribute to growth October 28, 2026 4

  5. Slide 5: Revenue by business area

    Revenue by business area Growth Growth in local Q1 Q1 in DKK Currencies DKKm 2007/08 2006/07 % % Respiratory Care 75.0 59.6 26 32 Cardiology 64.1 59.4 8 11 Neurology 17.6 15.3 15 20 Training 17.5 17.0 3 4 Immobilization and other products 13.2 12.4 6 16 Total 187.4 163.7 14 19 Respiratory Care Cardi

  6. Slide 6: Revenue by geographical region

    Revenue by geographical region Growth Growth in local Q1 Q1 in DKK currencies DKKm 2007/08 2006/07 % % USA 52.2 40.9 28 44 Europe 122.9 112.6 9 10 Other 12.3 10.2 21 21 Total 187.4 163.7 14 19 Europe USA  Growth exceeds market growth  Sales up 44%  Most customers have started trading with Ambu ag

  7. Slide 7: Operating profit (EBIT)

    Operating profit (EBIT)  Increase in EBIT of 76% in Q1 2007/08 to DKK 16m against DKK 9m last year  The improvement is primarily attributable to higher revenue  Developments in exchange rates only had a limited effect on EBIT  EBIT margin of 8.8% against 5.7% in Q1 2006/07 October 28, 2026 7

  8. Slide 8: Cash flow

    Cash flow  Cash flows from operating activities of DKK 20m against DKK 10m in Q1 2006/07  Positive free cash flow of DKK 16m against a negative free cash flow of DKK 2m in Q1 2006/07  The improvement is primarily attributable to improved earnings and lower investments October 28, 2026 8

  9. Slide 9: Situation in the USA

    Situation in the USA  Decision not to go ahead with specially discounted sales towards the end of 2006/07  Subsequent active targeting of customers  The sales force primarily focuses on customers with considerable potential  Focused sales efforts are continued October 28, 2026 9

  10. Slide 10: Reorganisation of the development area

    Reorganisation of the development area N ew P la tfo rm I n n ov a tion N ew Pro d u ct I n n ova tion L o cal R & D N e w p ro d u cts N ew fa m ily m em b e r s D en m ark a n d A s ia w ith in ex is tin g an d n ew g en eratio n s I m p ro v em en ts an d v arian ts b u s in es s areas o f ex is

  11. Slide 11: New products

    New products  No new products launched in Q1 2007/08  Focus on a number of new development activities  In the rest of 2007/08, 2–3 improved products or new variants will be launched within all 5 business areas  The products launched in 2006/07 have all been positively received by the market, and

  12. Slide 12: Reorganisation of the marketing area

    Reorganisation of the marketing area P o rtfo lio Ma n ag em ent Ma rket S up p o rt S ea rch  Portfolio managers within each individual business area. Improve knowledge of the market, optimise product portfolio, launch products and ensure product performance.  Market support – support of subsidia

  13. Slide 13: Patent case concerning laryngeal mask – status

    Patent case concerning laryngeal mask – status Autumn 2005 LMA institutes legal proceedings against Ambu Germany claiming infringement of a German patent concerning the reinforcement of the tip of the laryngeal mask August 2006 Decision announced. Ambu is infringing patent August 2006 Launch of new

  14. Slide 14: Agenda

    Agenda  Developments in Q1  Outlook for 2007/08  Focus areas in the coming period October 28, 2026 14

  15. Slide 15: The outlook for 2007/08 is unchanged

    The outlook for 2007/08 is unchanged  Growth in revenue of approx. 8% measured in local currencies, corresponding to approx. DKK 750m (USD: 500)  EBIT margin of 11.5-12%  Profit before tax of 10.5-11% of revenue, or approx. DKK 80m  Free cash flow of approx. DKK 45m (with investments amounting t

  16. Slide 16: Agenda

    Agenda  Developments in Q1  Outlook for 2007/08  Focus areas in the coming period October 28, 2026 16

  17. Slide 17: Focus areas

    Focus areas  Efficient implementation of changes within development as well as sales and marketing  Launch of new and improved products  Ensure growth in the USA  Continued streamlining of production  Focus on reducing unit costs and other costs through improved purchasing of raw materials and

  18. Slide 18: Questions

    Questions

  19. Slide 19: For further information, please visit www.ambu.com

    For further information, please visit www.ambu.com October 28, 2026 19

Ambu — Q1 2007/08 Earnings Presentation on 6ix